{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T21:00:27Z","timestamp":1784926827192,"version":"3.55.0"},"reference-count":91,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Treatments for lung cancer have advanced significantly over the last 2 decades, improving survival and long-term outcomes. However, lung cancer mortality remains high, and cures for metastatic disease have remained elusive. Here, we outline recent advances in our understanding of lung cancer biology and areas of interest for future therapeutic development, with a focus on resistance mechanisms, tumor heterogeneity, plasticity, minimal residual disease, and the tumor microenvironment. A comprehensive understanding of how these areas influence tumor biology will be essential for the development of future lung cancer therapies and to improve the care of lung cancer patients.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000841","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:00:29Z","timestamp":1784923229000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Basic and Translational Research Advances in NSCLC"],"prefix":"10.1097","volume":"32","author":[{"given":"Rajal","family":"Sharma","sequence":"first","affiliation":[{"name":"Yale Cancer Center"},{"name":"Department of Internal Medicine, Section of Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Politi","sequence":"additional","affiliation":[{"name":"Yale Cancer Center"},{"name":"Department of Internal Medicine, Section of Medical Oncology"},{"name":"Department of Pathology, Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7]]},"reference":[{"key":"R1-20260724","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","article-title":"Non-small-cell lung cancer","volume":"10","author":"Hendriks","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20260724","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc.2017.84","article-title":"Understanding and targeting resistance mechanisms in NSCLC","volume":"17","author":"Rotow","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"R3-20260724","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/s41571-025-01061-7","article-title":"Treatment of NSCLC after chemoimmunotherapy\u2014are we making headway?","volume":"22","author":"Reck","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"R4-20260724","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41571-025-01021-1","article-title":"Tumour and microenvironment crosstalk in NSCLC progression and response to therapy","volume":"22","author":"Rahal","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"R5-20260724","doi-asserted-by":"crossref","first-page":"e260017","DOI":"10.6004\/jnccn.2026.0017","article-title":"Non-small cell lung cancer, version 4.2026, NCCN Clinical Practice Guidelines In Oncology","volume":"24","author":"Riely","year":"2026","journal-title":"J Natl Compr Canc Netw"},{"key":"R6-20260724","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"R7-20260724","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41571-025-01085-z","article-title":"Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC\u2014mechanisms and evolving treatment approaches","volume":"23","author":"Zhao","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"key":"R8-20260724","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"key":"R9-20260724","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"R10-20260724","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J Clin Oncol"},{"key":"R11-20260724","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial","volume":"25","author":"Smit","year":"2024","journal-title":"Lancet Oncol"},{"key":"R12-20260724","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa2512071","article-title":"Sacituzumab tirumotecan in EGFR-TKI-resistant, EGFR-mutated advanced NSCLC","volume":"394","author":"Fang","year":"2026","journal-title":"N Engl J Med"},{"key":"R13-20260724","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.annonc.2026.02.014","article-title":"Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD","volume":"37","author":"Riess","year":"2026","journal-title":"Ann Oncol"},{"key":"R14-20260724","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"key":"R15-20260724","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMoa2600752","article-title":"Setidegrasib in advanced non-small-cell lung cancer and pancreatic cancer","volume":"394","author":"Park","year":"2026","journal-title":"N Engl J Med"},{"key":"R16-20260724","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.cell.2025.12.049","article-title":"Hallmarks of cancer\u2014then and now, and beyond","volume":"189","author":"Hanahan","year":"2026","journal-title":"Cell"},{"key":"R17-20260724","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"R18-20260724","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov"},{"key":"R19-20260724","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/ng0696-210","article-title":"A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer","volume":"13","author":"Chen","year":"1996","journal-title":"Nat Genet"},{"key":"R20-20260724","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"R21-20260724","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Memon","year":"2024","journal-title":"Cancer Cell"},{"key":"R22-20260724","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ccell.2025.12.002","article-title":"Targeting STING to generate therapeutic anti-tumor immunity","volume":"44","author":"Fahey","year":"2026","journal-title":"Cancer Cell"},{"key":"R23-20260724","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41586-024-07943-7","article-title":"CTLA4 blockade abrogates KEAP1\/STK11-related resistance to PD-(L)1 inhibitors","volume":"635","author":"Skoulidis","year":"2024","journal-title":"Nature"},{"key":"R24-20260724","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov"},{"key":"R25-20260724","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer\u2014a meta-analysis","volume":"12","author":"Lee","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R26-20260724","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jtho.2018.03.035","article-title":"A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naive patients with advanced NSCLC","volume":"13","author":"Lisberg","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R27-20260724","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.immuni.2021.04.004","article-title":"MDSC: markers, development, states, and unaddressed complexity","volume":"54","author":"Hegde","year":"2021","journal-title":"Immunity"},{"key":"R28-20260724","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41586-023-06797-9","article-title":"An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis","volume":"625","author":"LaMarche","year":"2024","journal-title":"Nature"},{"key":"R29-20260724","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/s41586-025-09493-y","article-title":"Myeloid progenitor dysregulation fuels immunosuppressive macrophages in tumours","volume":"646","author":"Hegde","year":"2025","journal-title":"Nature"},{"key":"R30-20260724","doi-asserted-by":"crossref","first-page":"155615","DOI":"10.1016\/j.metabol.2023.155615","article-title":"Targeting the dynamics of cancer metabolism in the era of precision oncology","volume":"145","author":"Zheng","year":"2023","journal-title":"Metabolism"},{"key":"R31-20260724","doi-asserted-by":"crossref","first-page":"e20231106","DOI":"10.1084\/jem.20231106","article-title":"Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"222","author":"Robles-Oteiza","year":"2025","journal-title":"J Exp Med"},{"key":"R32-20260724","doi-asserted-by":"crossref","first-page":"e124989","DOI":"10.1172\/jci.insight.124989","article-title":"Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma","volume":"4","author":"Najjar","year":"2019","journal-title":"JCI Insight"},{"key":"R33-20260724","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"R34-20260724","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/s41591-018-0045-3","article-title":"Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing","volume":"24","author":"Guo","year":"2018","journal-title":"Nat Med"},{"key":"R35-20260724","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.annonc.2021.11.008","article-title":"Anti-TIGIT to overcome resistance to immune checkpoint inhibitors in lung cancer: limits and potentials","volume":"33","author":"Attili","year":"2022","journal-title":"Ann Oncol"},{"key":"R36-20260724","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00262-020-02735-0","article-title":"Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives","volume":"70","author":"Qu","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"R37-20260724","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","article-title":"Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial","volume":"27","author":"Creelan","year":"2021","journal-title":"Nat Med"},{"key":"R38-20260724","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41586-025-09655-y","article-title":"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade","volume":"647","author":"Grippin","year":"2025","journal-title":"Nature"},{"key":"R39-20260724","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1038\/s41467-025-60281-8","article-title":"TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I\/II dose-escalation study","volume":"16","author":"Emmers","year":"2025","journal-title":"Nat Commun"},{"key":"R40-20260724","doi-asserted-by":"crossref","first-page":"eadf1329","DOI":"10.1126\/science.adf1329","article-title":"Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients","volume":"384","author":"Mathew","year":"2024","journal-title":"Science"},{"key":"R41-20260724","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/jama.2024.10613","article-title":"Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial","volume":"332","author":"Investigators","year":"2024","journal-title":"JAMA"},{"key":"R42-20260724","doi-asserted-by":"crossref","first-page":"17588359251386611","DOI":"10.1177\/17588359251386611","article-title":"Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1, or KRAS: the TRITON study","volume":"17","author":"Skoulidis","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"R43-20260724","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cell.2017.10.022","article-title":"Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer","volume":"171","author":"Topper","year":"2017","journal-title":"Cell"},{"key":"R44-20260724","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/s41591-025-04189-2","article-title":"Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial","volume":"32","author":"Porcari","year":"2026","journal-title":"Nat Med"},{"key":"R45-20260724","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat Med"},{"key":"R46-20260724","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41590-024-01792-2","article-title":"Human lung cancer harbors spatially organized stem-immunity hubs associated with response to immunotherapy","volume":"25","author":"Chen","year":"2024","journal-title":"Nat Immunol"},{"key":"R47-20260724","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41588-024-01998-y","article-title":"Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer","volume":"57","author":"Yan","year":"2025","journal-title":"Nat Genet"},{"key":"R48-20260724","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Sautes-Fridman","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"R49-20260724","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","article-title":"Neoantigen-directed immune escape in lung cancer evolution","volume":"567","author":"Rosenthal","year":"2019","journal-title":"Nature"},{"key":"R50-20260724","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nrc1586","article-title":"Immunosuppressive networks in the tumour environment and their therapeutic relevance","volume":"5","author":"Zou","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"R51-20260724","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/s41591-020-0900-x","article-title":"Geospatial immune variability illuminates differential evolution of lung adenocarcinoma","volume":"26","author":"AbdulJabbar","year":"2020","journal-title":"Nat Med"},{"key":"R52-20260724","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"R53-20260724","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41568-024-00734-2","article-title":"The evolutionary theory of cancer: challenges and potential solutions","volume":"24","author":"Laplane","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"R54-20260724","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41586-023-05783-5","article-title":"The evolution of lung cancer and impact of subclonal selection in TRACERx","volume":"616","author":"Frankell","year":"2023","journal-title":"Nature"},{"key":"R55-20260724","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41586-023-05729-x","article-title":"The evolution of non-small cell lung cancer metastases in TRACERx","volume":"616","author":"Al Bakir","year":"2023","journal-title":"Nature"},{"key":"R56-20260724","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","article-title":"Tracking the evolution of non-small-cell lung cancer","volume":"376","author":"Jamal-Hanjani","year":"2017","journal-title":"N Engl J Med"},{"key":"R57-20260724","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41586-023-05706-4","article-title":"Genomic-transcriptomic evolution in lung cancer and metastasis","volume":"616","author":"Martinez-Ruiz","year":"2023","journal-title":"Nature"},{"key":"R58-20260724","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41591-021-01233-9","article-title":"Intratumoral heterogeneity in cancer progression and response to immunotherapy","volume":"27","author":"Vitale","year":"2021","journal-title":"Nat Med"},{"key":"R59-20260724","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41586-025-09985-x","article-title":"Critical role for a high-plasticity cell state in lung cancer","volume":"651","author":"Chan","year":"2026","journal-title":"Nature"},{"key":"R60-20260724","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ccell.2020.06.012","article-title":"Emergence of a high-plasticity cell state during lung cancer evolution","volume":"38","author":"Marjanovic","year":"2020","journal-title":"Cancer Cell"},{"key":"R61-20260724","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.jtho.2025.06.012","article-title":"Molecular landscape and therapeutic strategies of lung cancer lineage plasticity","volume":"20","author":"Banerjee","year":"2025","journal-title":"J Thorac Oncol"},{"key":"R62-20260724","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1158\/1078-0432.CCR-19-3563","article-title":"Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R63-20260724","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1158\/2159-8290.CD-20-1863","article-title":"Multiomic analysis of lung tumors defines pathways activated in neuroendocrine transformation","volume":"11","author":"Quintanal-Villalonga","year":"2021","journal-title":"Cancer Discov"},{"key":"R64-20260724","doi-asserted-by":"crossref","first-page":"eadj1415","DOI":"10.1126\/science.adj1415","article-title":"Lineage-specific intolerance to oncogenic drivers restricts histological transformation","volume":"383","author":"Gardner","year":"2024","journal-title":"Science"},{"key":"R65-20260724","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRAS(G12C) inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N Engl J Med"},{"key":"R66-20260724","doi-asserted-by":"crossref","first-page":"e20232028","DOI":"10.1084\/jem.20232028","article-title":"EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation","volume":"221","author":"Qin","year":"2024","journal-title":"J Exp Med"},{"key":"R67-20260724","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1158\/2159-8290.CD-12-0112","article-title":"Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1","volume":"2","author":"Byers","year":"2012","journal-title":"Cancer Discov"},{"key":"R68-20260724","doi-asserted-by":"crossref","first-page":"e197008","DOI":"10.1172\/jci.insight.197008","article-title":"EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy","volume":"11","author":"Ogino","year":"2026","journal-title":"JCI Insight"},{"key":"R69-20260724","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1038\/s41388-022-02375-x","article-title":"EZH2 endorses cell plasticity to non-small cell lung cancer cells facilitating mesenchymal to epithelial transition and tumour colonization","volume":"41","author":"Gallardo","year":"2022","journal-title":"Oncogene"},{"key":"R70-20260724","article-title":"EED maintains the small cell lung cancer neuroendocrine phenotype and drives lung cancer histological transformation","author":"Li","year":"2025","journal-title":"bioRxiv"},{"key":"R71-20260724","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1038\/s41467-022-31998-7","article-title":"Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1","volume":"13","author":"Chen","year":"2022","journal-title":"Nat Commun"},{"key":"R72-20260724","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13045-021-01186-z","article-title":"Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation","volume":"14","author":"Quintanal-Villalonga","year":"2021","journal-title":"J Hematol Oncol"},{"key":"R73-20260724","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1038\/ncomms4261","article-title":"Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma","volume":"5","author":"Han","year":"2014","journal-title":"Nat Commun"},{"key":"R74-20260724","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ccell.2024.01.012","article-title":"Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer","volume":"42","author":"Tong","year":"2024","journal-title":"Cancer Cell"},{"key":"R75-20260724","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1200\/JCO.18.01585","article-title":"EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes","volume":"37","author":"Marcoux","year":"2019","journal-title":"J Clin Oncol"},{"key":"R76-20260724","doi-asserted-by":"crossref","first-page":"6377","DOI":"10.1038\/ncomms7377","article-title":"RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer","volume":"6","author":"Niederst","year":"2015","journal-title":"Nat Commun"},{"key":"R77-20260724","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"key":"R78-20260724","doi-asserted-by":"crossref","first-page":"e2500538","DOI":"10.1200\/PO-25-00538","article-title":"Multi-institution analysis of tarlatamab for the treatment of EGFR-mutant transformed small cell lung cancer","volume":"9","author":"Cooper","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"R79-20260724","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm.4040","article-title":"Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition","volume":"22","author":"Hata","year":"2016","journal-title":"Nat Med"},{"key":"R80-20260724","doi-asserted-by":"crossref","first-page":"10690","DOI":"10.1038\/ncomms10690","article-title":"Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells","volume":"7","author":"Ramirez","year":"2016","journal-title":"Nat Commun"},{"key":"R81-20260724","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"R82-20260724","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ccell.2017.07.002","article-title":"Repression of stress-induced LINE-1 expression protects cancer cell subpopulations from lethal drug exposure","volume":"32","author":"Guler","year":"2017","journal-title":"Cancer Cell"},{"key":"R83-20260724","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/s43018-024-00819-9","article-title":"Targeting therapy-persistent residual disease","volume":"5","author":"Sun","year":"2024","journal-title":"Nat Cancer"},{"key":"R84-20260724","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41586-021-03796-6","article-title":"Cycling cancer persister cells arise from lineages with distinct programs","volume":"596","author":"Oren","year":"2021","journal-title":"Nature"},{"key":"R85-20260724","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.ccr.2013.05.003","article-title":"Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells","volume":"23","author":"Roesch","year":"2013","journal-title":"Cancer Cell"},{"key":"R86-20260724","doi-asserted-by":"crossref","first-page":"7690","DOI":"10.1038\/s41467-022-34889-z","article-title":"Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer","volume":"13","author":"Adua","year":"2022","journal-title":"Nat Commun"},{"key":"R87-20260724","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ccell.2015.03.008","article-title":"Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin beta1\/FAK signaling","volume":"27","author":"Hirata","year":"2015","journal-title":"Cancer Cell"},{"key":"R88-20260724","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41586-023-06303-1","article-title":"Therapy-induced APOBEC3A drives evolution of persistent cancer cells","volume":"620","author":"Isozaki","year":"2023","journal-title":"Nature"},{"key":"R89-20260724","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1158\/1078-0432.CCR-22-3146","article-title":"Early clearance of plasma epidermal growth factor receptor mutations as a predictor of outcome on osimertinib in advanced non-small cell lung cancer; exploratory analysis from AURA3 and FLAURA","volume":"29","author":"Gray","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R90-20260724","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/s41591-025-03577-y","article-title":"Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer","volume":"31","author":"Herbst","year":"2025","journal-title":"Nat Med"},{"key":"R91-20260724","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1200\/JCO.2016.66.7162","article-title":"Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer","volume":"34","author":"Oxnard","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000841","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:00:39Z","timestamp":1784923239000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":91,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000841","relation":{},"ISSN":["1540-336X"],"issn-type":[{"value":"1540-336X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-05-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}